BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Giralt S, Thall PF, Khouri I, Wang X, Braunschweig I, Ippolitti C, Claxton D, Donato M, Bruton J, Cohen A. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood. 2001;97:631-637. [PMID: 11157478 DOI: 10.1182/blood.v97.3.631] [Cited by in Crossref: 484] [Cited by in F6Publishing: 496] [Article Influence: 22.0] [Reference Citation Analysis]
Number Citing Articles
1 Farshbafnadi M, Razi S, Rezaei N. Transplantation. Clinical Immunology 2023. [DOI: 10.1016/b978-0-12-818006-8.00008-6] [Reference Citation Analysis]
2 Lee B, Rui-jeat F, Soon-keng C. Immunotherapy for Hematological Cancers. Handbook of Cancer and Immunology 2023. [DOI: 10.1007/978-3-030-80962-1_226-1] [Reference Citation Analysis]
3 Yanada M, Harada K, Shimomura Y, Arai Y, Konuma T. Conditioning regimens for allogeneic hematopoietic cell transplantation in acute myeloid leukemia: Real-world data from the Japanese registry studies. Front Oncol 2022;12:1050633. [PMID: 36505853 DOI: 10.3389/fonc.2022.1050633] [Reference Citation Analysis]
4 Wong JY, Liu A, Han C, Dandapani S, Schultheiss T, Palmer J, Yang D, Somlo G, Salhotra A, Hui S, Al Malki MM, Rosenthal J, Stein A. Total marrow irradiation (TMI): Addressing an unmet need in hematopoietic cell transplantation - a single institution experience review. Front Oncol 2022;12:1003908. [DOI: 10.3389/fonc.2022.1003908] [Reference Citation Analysis]
5 Bender JD, Toro HO, Benoit J, Howell JC, Badia P, Davies SM, Grimley MS, Jodele S, Phillips C, Burns K, Marsh R, Nelson A, Wallace G, Dandoy CE, Pate A, Strine AC, Frias O, Breech L, Rose SR, Hoefgen H, Khandelwal P, Myers KC. Reduced-Intensity Conditioning Mitigates Risk for Primary Ovarian Insufficiency but Does Not Decrease Risk for Infertility in Pediatric and Young Adult Survivors of Hematopoietic Stem Cell Transplantation. Transplantation and Cellular Therapy 2022. [DOI: 10.1016/j.jtct.2022.10.018] [Reference Citation Analysis]
6 Brandão SR, Carvalho F, Amado F, Ferreira R, Costa VM. Insights on the molecular targets of cardiotoxicity induced by anticancer drugs: A systematic review based on proteomic findings. Metabolism 2022;134:155250. [PMID: 35809654 DOI: 10.1016/j.metabol.2022.155250] [Reference Citation Analysis]
7 Del Galy AS, Rousseau A, Capes A, Michonneau D, Robin M, de Fontbrune FS, Xhaard A, Frieri C, Adès L, Raffoux E, Himberlin C, Baudet M, Peffault de Latour R, Socié G. Life expectancy and burden of late complications after reduced intensity conditioning allogeneic transplantation. Bone Marrow Transplant. [DOI: 10.1038/s41409-022-01715-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Guijarro F, Bataller A, Diaz-beyá M, Garrido A, Coll-ferrà C, Vives S, Salamero O, Valcárcel D, Tormo M, Arnan M, Sampol A, Castaño-díez S, Martínez C, Suárez-lledó M, Fernández-avilés F, Hernández-boluda JC, Ribera JM, Rovira M, Brunet S, Sierra J, Esteve J. Long-term outcomes in patients with relapsed/refractory acute myeloid leukemia and other high-risk myeloid malignancies after undergoing sequential conditioning regimen based on IDA-FLAG and high-dose melphalan. Bone Marrow Transplant. [DOI: 10.1038/s41409-022-01703-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Shimada H, Tanizawa A, Kondo T, Nagamura-Inoue T, Yasui M, Tojo A, Muramatsu H, Eto T, Doki N, Tanaka M, Sato M, Noguchi M, Uchida N, Takahashi Y, Sakata N, Ichinohe T, Hashii Y, Kato K, Atsuta Y, Ohashi K, On-Behalf-Of-The-Pediatric-And-Adult-Cml/Mpn-Working-Groups-Of-The-Japanese-Society-For-Transplantation-And-Cellular-Therapy. Prognostic Factors for Outcomes of Allogeneic HSCT for Children and Adolescents/Young Adults with CML in the TKI Era. Transplant Cell Ther 2022:S2666-6367(22)01228-3. [PMID: 35447373 DOI: 10.1016/j.jtct.2022.04.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Kurosawa S, Shimomura Y, Itonaga H, Najima Y, Kobayashi T, Ozawa Y, Kanda Y, Kako S, Kawakita T, Matsuoka K, Maruyama Y, Ota S, Nakazawa H, Imada K, Kimura T, Kanda J, Fukuda T, Atsuta Y, Ishiyama K. Myeloablative versus reduced-intensity conditioning with fludarabine/busulfan for myelodysplastic syndrome: A propensity score-matched analysis. Transplantation and Cellular Therapy 2022. [DOI: 10.1016/j.jtct.2022.03.011] [Reference Citation Analysis]
11 Saraceni F, Scortechini I, Fiorentini A, Dubbini MV, Mancini G, Federici I, Colaneri FR, Lotito AF, Guerzoni S, Puglisi B, Olivieri A. Conditioning Regimens for Frail Patients with Acute Leukemia Undergoing Allogeneic Stem Cell Transplant: How to Strike Gently. Clin Hematol Int 2021;3:153-60. [PMID: 34938987 DOI: 10.2991/chi.k.210731.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
12 Li G, Sun Z, Geng L, Wan X, Zhu X, Tang B, Tong J, Yao W, Song K, Qiang P, Zhang L, Zhang X, Zhang S, Liu H. Clinical outcome of cord blood transplantation for nine children with juvenile myelomonocytic leukemia receiving fludarabine-busulfan-cyclophosphamide-based conditioning. Pediatr Transplant 2021;:e14181. [PMID: 34747111 DOI: 10.1111/petr.14181] [Reference Citation Analysis]
13 Chen X, Liu F, Chen B, Wu H, Li K, Xie Y, Kuang W, Li Z. Novel lysosome-targeted anticancer fluorescent agents used in zebrafish and nude mouse tumour imaging. Front Chem Sci Eng 2022;16:112-20. [DOI: 10.1007/s11705-021-2075-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
14 Kurosawa S, Shimomura Y, Itonaga H, Najima Y, Kobayashi T, Ozawa Y, Kanda Y, Kako S, Kawakita T, Matsuoka KI, Maruyama Y, Ota S, Nakazawa H, Imada K, Kanda J, Fukuda T, Atsuta Y, Aoki J. Fludarabine/busulfan versus busulfan/cyclophosphamide as myeloablative conditioning for myelodysplastic syndrome: a propensity score-matched analysis. Bone Marrow Transplant 2021. [PMID: 34489555 DOI: 10.1038/s41409-021-01447-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Gagelmann N, Kröger N. Dose intensity for conditioning in allogeneic hematopoietic cell transplantation: can we recommend "when and for whom" in 2021? Haematologica 2021;106:1794-804. [PMID: 33730842 DOI: 10.3324/haematol.2020.268839] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
16 Sharma N, Zhao Q, Ni B, Elder P, Puto M, Benson DM, Rosko A, Chaudhry M, Devarakonda S, Bumma N, Khan A, Vasu S, Jaglowski S, William BM, Mims A, Choe H, Larkin K, Brammer J, Wall S, Grieselhuber N, Saad A, Penza S, Efebera Y. Effect of Early Post-Transplantation Tacrolimus Concentration on the Risk of Acute Graft-Versus-Host Disease in Allogenic Stem Cell Transplantation. Cancers (Basel) 2021;13:613. [PMID: 33557088 DOI: 10.3390/cancers13040613] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
17 Bajel A. Transplant Pharmacology and Conditioning Therapy. Contemporary Bone Marrow Transplantation 2021. [DOI: 10.1007/978-3-030-36358-1_22] [Reference Citation Analysis]
18 Saraceni F, Labopin M, Forcade E, Kröger N, Socié G, Niittyvuopio R, Cornelissen JJ, Labussière-Wallet H, Blaise D, Choi G, Byrne JL, Guillerm G, Marchand T, Esteve J, Bazarbachi A, Savani B, Olivieri A, Nagler A, Mohty M. Allogeneic stem cell transplant in patients with acute myeloid leukemia and karnofsky performance status score less than or equal to 80%: A study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation (EBMT). Cancer Med 2021;10:23-33. [PMID: 33242374 DOI: 10.1002/cam4.3593] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
19 Liu R, Li D, Sun F, Rampoldi A, Maxwell JT, Wu R, Fischbach P, Castellino SM, Du Y, Fu H, Mandawat A, Xu C. Melphalan induces cardiotoxicity through oxidative stress in cardiomyocytes derived from human induced pluripotent stem cells. Stem Cell Res Ther 2020;11:470. [PMID: 33153480 DOI: 10.1186/s13287-020-01984-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
20 Ciurea SO, Kongtim P, Varma A, Rondon G, Chen J, Srour S, Bashir Q, Alousi A, Mehta R, Oran B, Popat U, Hosing C, Olson A, Daver N, Konopleva M, Champlin RE. Is there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation? Blood 2020;135:449-52. [PMID: 31826244 DOI: 10.1182/blood.2019003662] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 8.0] [Reference Citation Analysis]
21 Rosenthal J. Reduced Intensity Conditioning Regimens in Combination with Total Marrow and Lymphoid Irradiation. Total Marrow Irradiation 2020. [DOI: 10.1007/978-3-030-38692-4_5] [Reference Citation Analysis]
22 Bajel A. Transplant Pharmacology and Conditioning Therapy. Contemporary Bone Marrow Transplantation 2020. [DOI: 10.1007/978-3-319-64938-2_22-1] [Reference Citation Analysis]
23 Higgins A, Khan Z, Coddington CC, Hashmi SK, Hefazi M, Alkhateeb H, Litzow MR, Hogan WJ, Cathcart-Rake E, Thompson CA, Patnaik MM. Utilization and Outcomes of Fertility Preservation Techniques in Women Undergoing Allogeneic Hematopoietic Cell Transplant. Biol Blood Marrow Transplant 2019;25:1232-9. [PMID: 30772513 DOI: 10.1016/j.bbmt.2019.02.013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
24 Saini NY, Saliba RM, Rondon G, Maadani F, Popat U, Hosing CM, Oran B, Bashir Q, Olson A, Nieto Y, Alousi A, Kebriaei P, Srour S, Mehta R, Anderlini P, Shpall EJ, Qazilbash MH, Khouri IF, Fayad L, Lee H, Fowler N, Parmar S, Westin J, Hagemeister F, Champlin RE, Ciurea SO. Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma. Biol Blood Marrow Transplant 2019;25:1340-6. [PMID: 30763728 DOI: 10.1016/j.bbmt.2019.02.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
25 Yan L, Gulbis A. High-Dose Chemotherapy Regimens. Hematopoietic Cell Transplantation for Malignant Conditions 2019. [DOI: 10.1016/b978-0-323-56802-9.00003-1] [Reference Citation Analysis]
26 Mehta RS, Weisdorf D. History and Current Status of Hematopoietic Cell Transplantation. Hematopoietic Cell Transplantation for Malignant Conditions 2019. [DOI: 10.1016/b978-0-323-56802-9.00001-8] [Reference Citation Analysis]
27 Kawano N, Yoshida S, Shimonodan H, Kuriyama T, Ono N, Himeji D, Tochigi T, Nakaike T, Shimokawa T, Urata S, Yamashita K, Ito M, Koketsu H, Toyofuku A, Muranaka T, Marutsuka K, Mashiba K, Kikuchi I, Makino S, Ochiai H, Shimoda K, Nagafuji K, Mori Y, Miyamoto T, Akashi K. Clinical Features and Treatment Outcomes of Hematopoietic Stem Cell Transplantation During 2006-2016 at a Single Institution in Miyazaki Prefecture. Journal of Hematopoietic Cell Transplantation 2019;8:122-134. [DOI: 10.7889/hct-18-022] [Reference Citation Analysis]
28 Tomlinson B, de Lima M. Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia. Hematopoietic Cell Transplantation for Malignant Conditions 2019. [DOI: 10.1016/b978-0-323-56802-9.00009-2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
29 Chen GL, Hahn T, Wilding GE, Groman A, Hutson A, Zhang Y, Khan U, Liu H, Ross M, Bambach B, Higman M, Neppalli V, Sait S, Block AW, Wallace PK, Singh AK, McCarthy PL. Reduced-Intensity Conditioning with Fludarabine, Melphalan, and Total Body Irradiation for Allogeneic Hematopoietic Cell Transplantation: The Effect of Increasing Melphalan Dose on Underlying Disease and Toxicity. Biol Blood Marrow Transplant 2019;25:689-98. [PMID: 30300731 DOI: 10.1016/j.bbmt.2018.09.042] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
30 Jain T, Kunze KL, Temkit M, Partain DK, Patnaik MS, Slack JL, Khera N, Hogan WJ, Roy V, Noel P, Leis JF, Sproat LZ, Fauble V, Mesa RA, Palmer J. Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosis. Bone Marrow Transplant 2019;54:204-11. [PMID: 29795431 DOI: 10.1038/s41409-018-0226-1] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 6.0] [Reference Citation Analysis]
31 Lukanov T, Ivanova-shivarova M, Naumova E. Monitoring of Chimerism Following Hematopoietic Stem Cell Transplantation. Stem Cells in Clinical Practice and Tissue Engineering 2018. [DOI: 10.5772/67383] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
32 Xuan L, Fan Z, Zhang Y, Zhou H, Huang F, Dai M, Nie D, Lin D, Xu N, Guo X, Jiang Q, Sun J, Xiao Y, Liu Q. Sequential intensified conditioning followed by prophylactic DLI could reduce relapse of refractory acute leukemia after allo-HSCT. Oncotarget 2016;7:32579-91. [PMID: 27081039 DOI: 10.18632/oncotarget.8691] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
33 Milano F, Heimfeld S, Joachim Deeg H. Alternative Sources of Hematopoietic Stem Cells and Their Clinical Applications. Neoplastic Diseases of the Blood 2018. [DOI: 10.1007/978-3-319-64263-5_55] [Reference Citation Analysis]
34 Brown VI. Historical Overview of Pediatric HSCT. Hematopoietic Stem Cell Transplantation for the Pediatric Hematologist/Oncologist 2018. [DOI: 10.1007/978-3-319-63146-2_2] [Reference Citation Analysis]
35 Ago H. Advances and Perspective in Allogeneic Hematopoietic Cell Transplantation for Elderly Patients. Journal of Hematopoietic Cell Transplantation 2018;7:73-81. [DOI: 10.7889/hct-17-020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
36 Heidenreich D, Klein S. Allogene Stammzelltransplantation bei älteren komorbiden Patienten. Geriatrische Onkologie 2018. [DOI: 10.1007/978-3-662-48727-3_9] [Reference Citation Analysis]
37 Miyashita E, Miyoshi Y, Namba N, Ohta H, Yoshida H, Miyamura T, Hashii Y, Ozono K. Endocrine late effects following allogeneic hematopoietic stem cell transplantation with non-myeloablative conditioning. Journal of Hematopoietic Cell Transplantation 2018;7:90-97. [DOI: 10.7889/hct-16-033] [Reference Citation Analysis]
38 Zeidner JF, Kanakry CG, Luznik L. Hematopoietic Stem Cell Transplantation for Cancer. The American Cancer Society's Principles of Oncology 2017. [DOI: 10.1002/9781119468868.ch22] [Reference Citation Analysis]
39 Wong JYC, Hui S, Dandapani SV, Liu A. Biologic and Image Guided Systemic Radiotherapy. Cancer Treatment and Research 2017. [DOI: 10.1007/978-3-319-53235-6_8] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
40 Morishita T, Tsushita N, Imai K, Sakai T, Miyao K, Sakemura R, Kato T, Niimi K, Ono Y, Sawa M. The Efficacy of an Oral Elemental Diet in Patients Undergoing Hematopoietic Stem Cell Transplantation. Intern Med 2016;55:3561-9. [PMID: 27980254 DOI: 10.2169/internalmedicine.55.7310] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
41 van Besien K, Koshy N, Gergis U, Mayer S, Cushing M, Rennert H, Reich-Slotky R, Mark T, Pearse R, Rossi A, Phillips A, Vasovic L, Ferrante R, Hsu YM, Shore T. Haplo-cord transplant: HLA-matching determines graft dominance. Leuk Lymphoma 2017;58:1512-4. [PMID: 27786572 DOI: 10.1080/10428194.2016.1248964] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
42 Miyamoto T, Takashima S, Kato K, Takase K, Yoshimoto G, Yoshida S, Henzan H, Osaki K, Kamimura T, Iwasaki H, Eto T, Teshima T, Nagafuji K, Akashi K. Comparison of cyclosporine and tacrolimus combined with mycophenolate mofetil in prophylaxis for graft-versus-host disease after reduced-intensity umbilical cord blood transplantation. Int J Hematol 2017;105:92-9. [PMID: 27686673 DOI: 10.1007/s12185-016-2093-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
43 Kim H, Lee JH, Joo YD, Bae SH, Lee SM, Jo JC, Choi Y, Lee JH, Kim DY, Ryoo HM, Lee KH; CoOperative Study Group A for Hematology (COSAH). Comparable Allogeneic Hematopoietic Cell Transplantation Outcome of a Haplo-Identical Family Donor with an Alternative Donor in Adult Aplastic Anemia. Acta Haematol 2016;136:129-39. [PMID: 27409595 DOI: 10.1159/000445820] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
44 Gaballa S, Ge I, El Fakih R, Brammer JE, Kongtim P, Tomuleasa C, Wang SA, Lee D, Petropoulos D, Cao K, Rondon G, Chen J, Hammerstrom A, Lombardi L, Alatrash G, Korbling M, Oran B, Kebriaei P, Ahmed S, Shah N, Rezvani K, Marin D, Bashir Q, Alousi A, Nieto Y, Qazilbash M, Hosing C, Popat U, Shpall EJ, Khouri I, Champlin RE, Ciurea SO. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation. Cancer 2016;122:3316-26. [PMID: 27404668 DOI: 10.1002/cncr.30180] [Cited by in Crossref: 62] [Cited by in F6Publishing: 66] [Article Influence: 8.9] [Reference Citation Analysis]
45 van Besien K, Koshy N, Gergis U, Mayer S, Cushing M, Rennert H, Reich-Slotky R, Mark T, Pearse R, Rossi A, Phillips A, Vasovic L, Ferrante R, Hsu YM, Shore T. Cord blood chimerism and relapse after haplo-cord transplantation. Leuk Lymphoma 2017;58:288-97. [PMID: 27333804 DOI: 10.1080/10428194.2016.1190970] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
46 Dai Z, Liu J, Zhang WG, Cao X, Zhang Y, Dai Z. Fludarabine and busulfan as a reduced-toxicity myeloablative conditioning regimen in allogeneic hematopoietic stem cell transplantation for acute leukemia patients. Mol Clin Oncol 2016;4:667-71. [PMID: 27073687 DOI: 10.3892/mco.2016.765] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
47 Patir P, Vural F. Treatment of mycosis fungoides, in the era of stem cell transplantation. World J Dermatol 2016; 5(1): 52-56 [DOI: 10.5314/wjd.v5.i1.52] [Reference Citation Analysis]
48 Wong JY, Schultheiss T. Radiotherapeutic Principles of Hematopoietic Cell Transplantation. Thomas’ Hematopoietic Cell Transplantation 2016. [DOI: 10.1002/9781118416426.ch22] [Reference Citation Analysis]
49 Heidenreich D, Klein S. Allogene Stammzelltransplantation bei älteren komorbiden Patienten. Geriatrische Onkologie 2016. [DOI: 10.1007/978-3-662-49083-9_9-1] [Reference Citation Analysis]
50 Sandmaier BM, Storb R. Reduced-intensity Allogeneic Transplantation Regimens. Thomas’ Hematopoietic Cell Transplantation 2016. [DOI: 10.1002/9781118416426.ch21] [Reference Citation Analysis]
51 Van Deerlin VM, Reshef R. Chimerism Testing in Allogeneic Hematopoietic Stem Cell Transplantation. Molecular Pathology in Clinical Practice 2016. [DOI: 10.1007/978-3-319-19674-9_56] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
52 Oostvogels R, Lokhorst HM, Mutis T. Minor histocompatibility Ags: identification strategies, clinical results and translational perspectives. Bone Marrow Transplant 2016;51:163-71. [PMID: 26501766 DOI: 10.1038/bmt.2015.256] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
53 Komanduri KV, Levine RL. Diagnosis and Therapy of Acute Myeloid Leukemia in the Era of Molecular Risk Stratification. Annu Rev Med 2016;67:59-72. [PMID: 26473413 DOI: 10.1146/annurev-med-051914-021329] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 3.8] [Reference Citation Analysis]
54 Pingali SR, Champlin RE. Pushing the envelope-nonmyeloablative and reduced intensity preparative regimens for allogeneic hematopoietic transplantation. Bone Marrow Transplant 2015;50:1157-67. [PMID: 25985053 DOI: 10.1038/bmt.2015.61] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
55 Di Stasi A, Milton DR, Poon LM, Hamdi A, Rondon G, Chen J, Pingali SR, Konopleva M, Kongtim P, Alousi A. Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors. Biol Blood Marrow Transplant. 2014;20:1975-1981. [PMID: 25263628 DOI: 10.1016/j.bbmt.2014.08.013] [Cited by in Crossref: 166] [Cited by in F6Publishing: 176] [Article Influence: 18.4] [Reference Citation Analysis]
56 AlJohani NI, Thompson K, Hasegawa W, White D, Kew A, Couban S. Non-myeloablative allogeneic hematopoietic transplantation for patients with hematologic malignancies: 9-year single-centre experience. Curr Oncol 2014;21:e434-40. [PMID: 24940103 DOI: 10.3747/co.21.1846] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
57 Gyurkocza B, Sandmaier BM. Conditioning regimens for hematopoietic cell transplantation: one size does not fit all. Blood. 2014;124:344-353. [PMID: 24914142 DOI: 10.1182/blood-2014-02-514778] [Cited by in Crossref: 307] [Cited by in F6Publishing: 325] [Article Influence: 34.1] [Reference Citation Analysis]
58 Alwasaidi T, Bredeson C. Peripheral blood stem cells or bone marrow as the graft source for allogeneic hematopoietic cell transplantation? Journal of Taibah University Medical Sciences 2014;9:91-99. [DOI: 10.1016/j.jtumed.2013.11.004] [Reference Citation Analysis]
59 Muffly LS, Kocherginsky M, Stock W, Chu Q, Bishop MR, Godley LA, Kline J, Liu H, Odenike OM, Larson RA, van Besien K, Artz AS. Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients. Haematologica 2014;99:1373-9. [PMID: 24816237 DOI: 10.3324/haematol.2014.103655] [Cited by in Crossref: 164] [Cited by in F6Publishing: 173] [Article Influence: 18.2] [Reference Citation Analysis]
60 Gotoh M, Yoshizawa S, Katagiri S, Suguro T, Asano M, Kitahara T, Akahane D, Okabe S, Tauchi T, Ito Y, Ohyashiki K. A novel reduced-intensity umbilical cord blood transplantation using a recombinant G-CSF combined with high-dose Ara-C for active myeloid malignancies. Bone Marrow Transplant 2014;49:955-60. [PMID: 24732960 DOI: 10.1038/bmt.2014.66] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
61 Thatishetty AV, Agresti N, O'Brien CB. Chemotherapy-induced hepatotoxicity. Clin Liver Dis 2013;17:671-86, ix-x. [PMID: 24099024 DOI: 10.1016/j.cld.2013.07.010] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 3.1] [Reference Citation Analysis]
62 Chen GL, Zhang Y, Hahn T, Abrams S, Ross M, Liu H, McCarthy PL. Acute GVHD prophylaxis with standard-dose, micro-dose or no MTX after fludarabine/melphalan conditioning. Bone Marrow Transplant 2014;49:248-53. [PMID: 24162612 DOI: 10.1038/bmt.2013.167] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
63 Metheny L, Caimi P, de Lima M. Cord Blood Transplantation: Can We Make it Better? Front Oncol 2013;3:238. [PMID: 24062989 DOI: 10.3389/fonc.2013.00238] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
64 Yu ZP, Ding JH, Chen BA, Li YF, Ding BH, Qian J. An anti-human thymocyte globulin-based reduced-intensity conditioning regimen is associated with a higher quality of life and lower organ toxicity without affecting lymphocyte reconstitution. PLoS One 2013;8:e73755. [PMID: 24040055 DOI: 10.1371/journal.pone.0073755] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
65 Schlaak M, Pickenhain J, Theurich S, Skoetz N, von Bergwelt-Baildon M, Kurschat P. Allogeneic stem cell transplantation versus conventional therapy for advanced primary cutaneous T-cell lymphoma. Cochrane Database Syst Rev 2013;:CD008908. [PMID: 23986525 DOI: 10.1002/14651858.CD008908.pub3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
66 Fadilah SA, Aqilah MP. Promising role of reduced-toxicity hematopoietic stem cell transplantation (PART-I). Stem Cell Rev Rep 2012;8:1254-64. [PMID: 22836809 DOI: 10.1007/s12015-012-9401-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
67 Wahid SF. Indications and outcomes of reduced-toxicity hematopoietic stem cell transplantation in adult patients with hematological malignancies. Int J Hematol 2013;97:581-98. [PMID: 23585244 DOI: 10.1007/s12185-013-1313-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
68 Gutman JA, Heimfeld S, Deeg HJ. Alternative Sources of Hematopoietic Stem Cells and Their Clinical Applications. Neoplastic Diseases of the Blood 2013. [DOI: 10.1007/978-1-4614-3764-2_57] [Reference Citation Analysis]
69 Bayraktar UD, Bashir Q, Qazilbash M, Champlin RE, Ciurea SO. Fifty years of melphalan use in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2013;19:344-56. [PMID: 22922522 DOI: 10.1016/j.bbmt.2012.08.011] [Cited by in Crossref: 66] [Cited by in F6Publishing: 71] [Article Influence: 6.0] [Reference Citation Analysis]
70 Xuan L, Huang F, Fan Z, Zhou H, Zhang X, Yu G, Zhang Y, Liu C, Sun J, Liu Q. Effects of intensified conditioning on Epstein-Barr virus and cytomegalovirus infections in allogeneic hematopoietic stem cell transplantation for hematological malignancies. J Hematol Oncol 2012;5:46. [PMID: 22856463 DOI: 10.1186/1756-8722-5-46] [Cited by in Crossref: 47] [Cited by in F6Publishing: 53] [Article Influence: 4.3] [Reference Citation Analysis]
71 Reshef R, Luger SM, Hexner EO, Loren AW, Frey NV, Nasta SD, Goldstein SC, Stadtmauer EA, Smith J, Bailey S, Mick R, Heitjan DF, Emerson SG, Hoxie JA, Vonderheide RH, Porter DL. Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease. N Engl J Med 2012;367:135-45. [PMID: 22784116 DOI: 10.1056/NEJMoa1201248] [Cited by in Crossref: 201] [Cited by in F6Publishing: 206] [Article Influence: 18.3] [Reference Citation Analysis]
72 Wong JY, Forman S, Somlo G, Rosenthal J, Liu A, Schultheiss T, Radany E, Palmer J, Stein A. Dose escalation of total marrow irradiation with concurrent chemotherapy in patients with advanced acute leukemia undergoing allogeneic hematopoietic cell transplantation. Int J Radiat Oncol Biol Phys 2013;85:148-56. [PMID: 22592050 DOI: 10.1016/j.ijrobp.2012.03.033] [Cited by in Crossref: 58] [Cited by in F6Publishing: 47] [Article Influence: 5.3] [Reference Citation Analysis]
73 Platzbecker U, Schetelig J, Finke J, Trenschel R, Scott BL, Kobbe G, Schaefer-Eckart K, Bornhäuser M, Itzykson R, Germing U, Beelen D, Ehninger G, Fenaux P, Deeg HJ, Adès L; German MDS Study., Cooperative Transplant Study Group., Fred Hutchinson Cancer Research Center., Groupe Francophone des Myelodysplasies. Allogeneic hematopoietic cell transplantation in patients age 60-70 years with de novo high-risk myelodysplastic syndrome or secondary acute myelogenous leukemia: comparison with patients lacking donors who received azacitidine. Biol Blood Marrow Transplant 2012;18:1415-21. [PMID: 22579634 DOI: 10.1016/j.bbmt.2012.05.003] [Cited by in Crossref: 71] [Cited by in F6Publishing: 75] [Article Influence: 6.5] [Reference Citation Analysis]
74 Ballen K. How to manage the transplant question in myelofibrosis. Blood Cancer J 2012;2:e59. [PMID: 22829254 DOI: 10.1038/bcj.2012.3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
75 Ciurea SO, Saliba RM, Hamerschlak N, Karduss Aurueta AJ, Bassett R, Fernandez-Vina M, Petropoulos D, Worth LL, Chan KW, Couriel DR, Rondon G, Sharma M, Qazilbash M, Jones RB, Kebriaei P, McMannis J, Hosing CM, Nieto Y, Champlin RE, Shpall EJ, de Lima M. Fludarabine, melphalan, thiotepa and anti-thymocyte globulin conditioning for unrelated cord blood transplant. Leuk Lymphoma 2012;53:901-6. [PMID: 21988645 DOI: 10.3109/10428194.2011.631159] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
76 Vokurka S, Svoboda T, Karas M, Koza V, Jindra P, Kazakov D, Boudova L. Significant oral graft-versus-host disease after allogeneic stem cell transplantation with the FLU/MEL conditioning regimen. Med Sci Monit 2011;17:CR480-4. [PMID: 21873943 DOI: 10.12659/msm.881933] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
77 Champlin R, Jabbour E, Kebriaei P, Anderlini P, Andersson B, de Lima M. Allogeneic stem cell transplantation for chronic myeloid leukemia resistant to tyrosine kinase inhibitors. Clin Lymphoma Myeloma Leuk 2011;11 Suppl 1:S96-100. [PMID: 22035758 DOI: 10.1016/j.clml.2011.03.028] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
78 van Besien K, Stock W, Rich E, Odenike O, Godley LA, O'Donnell PH, Kline J, Nguyen V, Del Cerro P, Larson RA, Artz AS. Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012;18:913-921. [PMID: 22079470 DOI: 10.1016/j.bbmt.2011.10.041] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 2.6] [Reference Citation Analysis]
79 Liu H, Rich ES, Godley L, Odenike O, Joseph L, Marino S, Kline J, Nguyen V, Cunningham J, Larson RA. Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. Blood. 2011;118:6438-6445. [PMID: 21976674 DOI: 10.1182/blood-2011-08-372508] [Cited by in Crossref: 131] [Cited by in F6Publishing: 140] [Article Influence: 10.9] [Reference Citation Analysis]
80 Carvallo C, Childs R. Nonmyeloablative stem cell transplantation as immunotherapy for kidney cancer and other metastatic solid tumors. Cytotechnology 2003;41:197-206. [PMID: 19002956 DOI: 10.1023/A:1024839225920] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
81 Popat U, de Lima MJ, Saliba RM, Anderlini P, Andersson BS, Alousi AM, Hosing C, Nieto Y, Parmar S, Khouri IF, Kebriaei P, Qazilbash M, Champlin RE, Giralt SA. Long-term outcome of reduced-intensity allogeneic hematopoietic SCT in patients with AML in CR. Bone Marrow Transplant 2012;47:212-6. [PMID: 21423123 DOI: 10.1038/bmt.2011.61] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
82 Gyurkocza B, Rezvani A, Storb RF. Allogeneic hematopoietic cell transplantation: the state of the art. Expert Rev Hematol 2010;3:285-99. [PMID: 20871781 DOI: 10.1586/ehm.10.21] [Cited by in Crossref: 115] [Cited by in F6Publishing: 124] [Article Influence: 9.6] [Reference Citation Analysis]
83 Iguchi A, Kawamura N, Kobayashi R, Takezaki SI, Ohkura Y, Inamoto J, Ohshima J, Ichikawa M, Sato T, Kaneda M, Cho Y, Yamada M, Kobayashi I, Ariga T. Successful reduced-intensity SCT from unrelated cord blood in three patients with X-linked SCID. Bone Marrow Transplant 2011;46:1526-31. [PMID: 21258424 DOI: 10.1038/bmt.2010.338] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
84 Giralt S. TMLI: a better TBI or more of the same? Blood 2011;117:9-9. [DOI: 10.1182/blood-2010-10-312132] [Reference Citation Analysis]
85 Schlaak M, Theurich S, Skoetz N, Pickenhain J, Engert A, Kurschat P, Bergwelt-baildon M. Allogeneic stem cell transplantation versus conventional therapy for advanced primary cutaneous T cell lymphoma. Cochrane Database of Systematic Reviews 2010. [DOI: 10.1002/14651858.cd008908] [Reference Citation Analysis]
86 Stevenson W, Garcia‐manero G. Myelodysplastic Syndromes. Leukemias: Principles and Practice of Therapy 2010. [DOI: 10.1002/9781444327359.ch8] [Reference Citation Analysis]
87 Burnett AK. Management of acute myeloid leukemia. Management of Hematologic Malignancies 2010. [DOI: 10.1017/cbo9780511781926.002] [Reference Citation Analysis]
88 Kohrt HE, Pillai AB, Lowsky R, Strober S. NKT cells, Treg, and their interactions in bone marrow transplantation. Eur J Immunol 2010;40:1862-9. [PMID: 20583031 DOI: 10.1002/eji.201040394] [Cited by in Crossref: 55] [Cited by in F6Publishing: 59] [Article Influence: 4.2] [Reference Citation Analysis]
89 Rosenthal J, Wong J, Stein A, Qian D, Hitt D, Naeem H, Dagis A, Thomas SH, Forman S. Phase 1/2 trial of total marrow and lymph node irradiation to augment reduced-intensity transplantation for advanced hematologic malignancies. Blood 2011;117:309-15. [PMID: 20876852 DOI: 10.1182/blood-2010-06-288357] [Cited by in Crossref: 61] [Cited by in F6Publishing: 65] [Article Influence: 4.7] [Reference Citation Analysis]
90 Valdez BC, Andersson BS. Interstrand crosslink inducing agents in pretransplant conditioning therapy for hematologic malignancies. Environ Mol Mutagen 2010;51:659-68. [PMID: 20577993 DOI: 10.1002/em.20603] [Cited by in Crossref: 3] [Cited by in F6Publishing: 19] [Article Influence: 0.2] [Reference Citation Analysis]
91 Lee JH, Choi J, Kwon KA, Lee S, Oh SY, Kwon HC, Kim HJ, Han JY, Kim SH. Fludarabine-based myeloablative regimen as pretransplant conditioning therapy in adult acute leukemia/myelodysplastic syndrome: comparison with oral or intravenous busulfan with cyclophosphamide. Korean J Hematol 2010;45:102-8. [PMID: 21120188 DOI: 10.5045/kjh.2010.45.2.102] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
92 Patel SA, King CC, Lim PK, Habiba U, Dave M, Porecha R, Rameshwar P. Personalizing Stem Cell Research and Therapy: The Arduous Road Ahead or Missed Opportunity? Curr Pharmacogenomics Person Med 2010;8:25-36. [PMID: 20563265 DOI: 10.2174/1875692111008010025] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
93 Dhédin N, Vernant J. Allogreffe de cellules souches hématopoïétiques : réalisation et complications. EMC - Hématologie 2010;5:1-19. [DOI: 10.1016/s1155-1984(10)51289-5] [Reference Citation Analysis]
94 Imamura M, Tanaka J. Graft-versus-leukemia effect of nonmyeloablative stem cell transplantation. Korean J Intern Med 2009;24:287-98. [PMID: 19949725 DOI: 10.3904/kjim.2009.24.4.287] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
95 Ballen KK, Shrestha S, Sobocinski KA, Zhang MJ, Bashey A, Bolwell BJ, Cervantes F, Devine SM, Gale RP, Gupta V, Hahn TE, Hogan WJ, Kröger N, Litzow MR, Marks DI, Maziarz RT, McCarthy PL, Schiller G, Schouten HC, Roy V, Wiernik PH, Horowitz MM, Giralt SA, Arora M. Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant 2010;16:358-67. [PMID: 19879949 DOI: 10.1016/j.bbmt.2009.10.025] [Cited by in Crossref: 191] [Cited by in F6Publishing: 210] [Article Influence: 13.6] [Reference Citation Analysis]
96 References. Bone Marrow Transplant 2009;44:537-557. [DOI: 10.1038/bmt.2009.269] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
97 Ho VT, Aldridge J, Kim HT, Cutler C, Koreth J, Armand P, Antin JH, Soiffer RJ, Alyea EP. Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2009;15:844-50. [PMID: 19539216 DOI: 10.1016/j.bbmt.2009.03.017] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 2.9] [Reference Citation Analysis]
98 Andersson BS, de Lima M, Thall PF, Madden T, Russell JA, Champlin RE. Reduced-toxicity conditioning therapy with allogeneic stem cell transplantation for acute leukemia. Curr Opin Oncol 2009;21 Suppl 1:S11-5. [PMID: 19561406 DOI: 10.1097/01.cco.0000357469.83960.12] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
99 Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, Apperley J, Slavin S, Pasquini M, Sandmaier BM. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15:1628-1633. [PMID: 19896087 DOI: 10.1016/j.bbmt.2009.07.004] [Cited by in Crossref: 1114] [Cited by in F6Publishing: 1172] [Article Influence: 79.6] [Reference Citation Analysis]
100 van Besien K, Kunavakkam R, Rondon G, De Lima M, Artz A, Oran B, Giralt S. Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes. Biol Blood Marrow Transplant 2009;15:610-7. [PMID: 19361753 DOI: 10.1016/j.bbmt.2009.01.021] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 2.9] [Reference Citation Analysis]
101 Peres E, Levine JE, Khaled YA, Ibrahim RB, Braun TM, Krijanovski OI, Mineishi S, Abidi MH. Cardiac complications in patients undergoing a reduced-intensity conditioning hematopoietic stem cell transplantation. Bone Marrow Transplant 2010;45:149-52. [PMID: 19465940 DOI: 10.1038/bmt.2009.97] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 2.8] [Reference Citation Analysis]
102 Kohrt HE, Turnbull BB, Heydari K, Shizuru JA, Laport GG, Miklos DB, Johnston LJ, Arai S, Weng WK, Hoppe RT, Lavori PW, Blume KG, Negrin RS, Strober S, Lowsky R. TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. Blood 2009;114:1099-109. [PMID: 19423725 DOI: 10.1182/blood-2009-03-211441] [Cited by in Crossref: 132] [Cited by in F6Publishing: 138] [Article Influence: 9.4] [Reference Citation Analysis]
103 Ricci F, Tedeschi A, Morra E, Montillo M. Fludarabine in the treatment of chronic lymphocytic leukemia: a review. Ther Clin Risk Manag 2009;5:187-207. [PMID: 19436622 DOI: 10.2147/tcrm.s3688] [Cited by in Crossref: 6] [Cited by in F6Publishing: 22] [Article Influence: 0.4] [Reference Citation Analysis]
104 Lim ZY, Mufti GJ. The myelodysplastic syndromes. Hematopoietic Stem Cell Transplantation in Clinical Practice 2009. [DOI: 10.1016/b978-0-443-10147-2.50011-4] [Reference Citation Analysis]
105 Burnett AK, Knapper S. Acute myeloid leukemia. Hematopoietic Stem Cell Transplantation in Clinical Practice 2009. [DOI: 10.1016/b978-0-443-10147-2.50007-2] [Reference Citation Analysis]
106 Artz AS, Ershler WB. Management of the older patient. Hematopoietic Stem Cell Transplantation in Clinical Practice 2009. [DOI: 10.1016/b978-0-443-10147-2.50034-5] [Reference Citation Analysis]
107 Platzbecker U, Bornhäuser M, Germing U, Stumpf J, Scott BL, Kröger N, Schwerdtfeger R, Böhm A, Kobbe G, Theuser C, Rabitsch W, Valent P, Sorror ML, Ehninger G, Deeg HJ. Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS). Biol Blood Marrow Transplant 2008;14:1217-25. [PMID: 18940675 DOI: 10.1016/j.bbmt.2008.08.006] [Cited by in Crossref: 103] [Cited by in F6Publishing: 109] [Article Influence: 6.9] [Reference Citation Analysis]
108 Alyea EP, Li S, Kim HT, Cutler C, Ho V, Soiffer RJ, Antin JH. Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2008;14:920-6. [PMID: 18640576 DOI: 10.1016/j.bbmt.2008.05.024] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 2.6] [Reference Citation Analysis]
109 Andersson BS, de Lima M, Thall PF, Wang X, Couriel D, Korbling M, Roberson S, Giralt S, Pierre B, Russell JA, Shpall EJ, Jones RB, Champlin RE. Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. Biol Blood Marrow Transplant 2008;14:672-84. [PMID: 18489993 DOI: 10.1016/j.bbmt.2008.03.009] [Cited by in Crossref: 130] [Cited by in F6Publishing: 135] [Article Influence: 8.7] [Reference Citation Analysis]
110 Murashige N, Kami M, Mori S, Katayama Y, Kobayashi K, Onishi Y, Hori A, Kishi Y, Hamaki T, Tajima K, Kanda Y, Tanosaki R, Takaue Y. Characterization of acute graft-versus-host disease following reduced-intensity stem-cell transplantation from an HLA-identical related donor. Am J Hematol 2008;83:630-4. [PMID: 18454459 DOI: 10.1002/ajh.21197] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
111 Hari P, Carreras J, Zhang MJ, Gale RP, Bolwell BJ, Bredeson CN, Burns LJ, Cairo MS, Freytes CO, Goldstein SC, Hale GA, Inwards DJ, Lemaistre CF, Maharaj D, Marks DI, Schouten HC, Slavin S, Vose JM, Lazarus HM, van Besien K. Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning. Biol Blood Marrow Transplant 2008;14:236-45. [PMID: 18215784 DOI: 10.1016/j.bbmt.2007.11.004] [Cited by in Crossref: 136] [Cited by in F6Publishing: 141] [Article Influence: 9.1] [Reference Citation Analysis]
112 Mielcarek M, Storer BE, Sandmaier BM, Sorror ML, Maloney DG, Petersdorf E, Martin PJ, Storb R. Comparable outcomes after nonmyeloablative hematopoietic cell transplantation with unrelated and related donors. Biol Blood Marrow Transplant 2007;13:1499-507. [PMID: 18022580 DOI: 10.1016/j.bbmt.2007.09.004] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 2.3] [Reference Citation Analysis]
113 Alousi A, Lima MD. Ablative Preparative Regimens for Hematopoietic Stem Cell Transplantation. Hematopoietic Stem Cell Transplantation 2008. [DOI: 10.1007/978-1-59745-438-4_16] [Reference Citation Analysis]
114 Wetzler M. Chronic Myeloid Leukemia. Oncology. [DOI: 10.1007/0-387-31056-8_66] [Reference Citation Analysis]
115 Mohty M. Allogreffe de cellules souches hématopoïétiques avec conditionnement à intensité réduite: situation en 2007 et perspectives. Oncologie 2007;9:842-847. [DOI: 10.1007/s10269-007-0761-7] [Reference Citation Analysis]
116 Kebriaei P, Champlin R. The Role of Allogeneic Stem Cell Transplantation in the Therapy of Adult Acute Lymphoblastic Leukemia (ALL). Acute Leukemias. [DOI: 10.1007/978-3-540-72304-2_17] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
117 Jakubowski AA, Small TN, Young JW, Kernan NA, Castro-Malaspina H, Hsu KC, Perales MA, Collins N, Cisek C, Chiu M, van den Brink MR, O'Reilly RJ, Papadopoulos EB. T cell depleted stem-cell transplantation for adults with hematologic malignancies: sustained engraftment of HLA-matched related donor grafts without the use of antithymocyte globulin. Blood 2007;110:4552-9. [PMID: 17717135 DOI: 10.1182/blood-2007-06-093880] [Cited by in Crossref: 98] [Cited by in F6Publishing: 99] [Article Influence: 6.1] [Reference Citation Analysis]
118 Brunstein CG, Barker JN, Weisdorf DJ, DeFor TE, Miller JS, Blazar BR, McGlave PB, Wagner JE. Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. Blood. 2007;110:3064-3070. [PMID: 17569820 DOI: 10.1182/blood-2007-04-067215] [Cited by in Crossref: 418] [Cited by in F6Publishing: 439] [Article Influence: 26.1] [Reference Citation Analysis]
119 Kim I, Lee KH, Choi Y, Keam B, Koo NH, Yoon SS, Yoo KY, Park S, Kim BK. Allogeneic stem cell transplantation for patients with advanced hematological malignancies: comparison of fludarabine-based reduced intensity conditioning versus myeloablative conditioning. J Korean Med Sci 2007;22:227-34. [PMID: 17449929 DOI: 10.3346/jkms.2007.22.2.227] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
120 Shapira MY, Tsirigotis P, Resnick IB, Or R. Allogeneic bone marrow transplantation in the elderly: an emerging change in the transplantation field. Aging Health 2007;3:275-277. [DOI: 10.2217/1745509x.3.3.275] [Reference Citation Analysis]
121 Ballen KK, Spitzer TR, Yeap BY, McAfee S, Dey BR, Attar E, Haspel R, Kao G, Liney D, Alyea E. Double unrelated reduced-intensity umbilical cord blood transplantation in adults. Biol Blood Marrow Transplant. 2007;13:82-89. [PMID: 17222756 DOI: 10.1016/j.bbmt.2006.08.041] [Cited by in Crossref: 259] [Cited by in F6Publishing: 227] [Article Influence: 16.2] [Reference Citation Analysis]
122 Oran B, Giralt S, Saliba R, Hosing C, Popat U, Khouri I, Couriel D, Qazilbash M, Anderlini P, Kebriaei P, Ghosh S, Carrasco-Yalan A, de Meis E, Anagnostopoulos A, Donato M, Champlin RE, de Lima M. Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan. Biol Blood Marrow Transplant 2007;13:454-62. [PMID: 17382251 DOI: 10.1016/j.bbmt.2006.11.024] [Cited by in Crossref: 98] [Cited by in F6Publishing: 102] [Article Influence: 6.1] [Reference Citation Analysis]
123 Shore T. Stem cell transplantation for myelodysplastic syndromes: the lure of a cure. Curr Hematol Malig Rep 2007;2:3-8. [PMID: 20425382 DOI: 10.1007/s11899-007-0001-7] [Reference Citation Analysis]
124 Georges GE, Maris MB, Maloney DG, Sandmaier BM, Sorror ML, Shizuru JA, Lange T, Agura ED, Bruno B, McSweeney PA, Pulsipher MA, Chauncey TR, Mielcarek M, Storer BE, Storb R. Nonmyeloablative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myeloma. Biol Blood Marrow Transplant 2007;13:423-32. [PMID: 17287157 DOI: 10.1016/j.bbmt.2006.11.011] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 1.9] [Reference Citation Analysis]
125 Papadopoulos EB, Jakubowski AA. Novel approaches in allogeneic stem cell transplantation. Curr Oncol Rep 2006;8:325-36. [PMID: 16901394 DOI: 10.1007/s11912-006-0054-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
126 Chronic Myelogenous Leukemia. Wiley Handbook of Current and Emerging Drug Therapies 2006. [DOI: 10.1002/9780470041000.cedt008] [Reference Citation Analysis]
127 Sorror ML, Storb R. Hematopoietic Cell Transplantation after Nonmyeloablative Conditioning. Ernst Schering Research Foundation Workshop. [DOI: 10.1007/3-540-26843-x_10] [Reference Citation Analysis]
128 Martino R, Parody R, Fukuda T, Maertens J, Theunissen K, Ho A, Mufti GJ, Kroger N, Zander AR, Heim D, Paluszewska M, Selleslag D, Steinerova K, Ljungman P, Cesaro S, Nihtinen A, Cordonnier C, Vazquez L, López-Duarte M, Lopez J, Cabrera R, Rovira M, Neuburger S, Cornely O, Hunter AE, Marr KA, Dornbusch HJ, Einsele H. Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: A retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood 2006;108:2928-36. [PMID: 16720833 DOI: 10.1182/blood-2006-03-008706] [Cited by in Crossref: 102] [Cited by in F6Publishing: 107] [Article Influence: 6.0] [Reference Citation Analysis]
129 Ballen KK, Colvin G, Dey BR, Porter D, Westervelt P, Spitzer TR, Quesenberry PJ. Cellular immune therapy for refractory cancers: novel therapeutic strategies. Exp Hematol. 2005;33:1427-1435. [PMID: 16338484 DOI: 10.1016/j.exphem.2005.06.032] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
130 Stoppa A, Vey N, Bouabdallah R, Faucher C, Costello R, Coso D, Sainty D, Arnoulet C, Lafage M, Mozziconacci M, Blaise D, Gastaut J, Maraninchi D. Pronostic et traitement des leucémies aiguës myéloblastiques. EMC - Hématologie 2006;1:1-13. [DOI: 10.1016/s1155-1984(02)00041-9] [Reference Citation Analysis]
131 Matsui K, Tanaka Y, Matsuda K, Yamashita K, Shinohara K. A Case of Refractory Follicular Lymphoma Successfully Treated with Allogeneic Peripheral Blood Hematopoietic Stem Cell Transplantation following the Reduced Intensity Conditioning Regimen (RIST). Yamaguchi Medical Journal 2006;55:67-72. [DOI: 10.2342/ymj.55.67] [Reference Citation Analysis]
132 Shimoni A, Nagler A. Nonmyeloablative Stem Cell Transplantation in the Treatment of Hematologic Malignancies. Stem Cell and Gene-Based Therapy 2006. [DOI: 10.1007/1-84628-142-3_25] [Reference Citation Analysis]
133 Rytting ME, Choroszy MS, Petropoulos D, Chan KW. Acute Leukemia. Pediatric Oncology 2005. [DOI: 10.1007/978-0-387-24472-3_1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
134 Baron F, Storb R. Allogeneic hematopoietic cell transplantation as treatment for hematological malignancies: a review. Springer Semin Immunopathol 2004;26:71-94. [PMID: 15549304 DOI: 10.1007/s00281-004-0165-3] [Cited by in Crossref: 64] [Cited by in F6Publishing: 52] [Article Influence: 3.4] [Reference Citation Analysis]
135 Shimoni A, Nagler A. Clinical implications of minimal residual disease monitoring for stem cell transplantation after reduced intensity and nonmyeloablative conditioning. Acta Haematol 2004;112:93-104. [PMID: 15179009 DOI: 10.1159/000077564] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
136 Maris M, Storb R. The transplantation of hematopoietic stem cells after non-myeloablative conditioning: a cellular therapeutic approach to hematologic and genetic diseases. Immunol Res 2003;28:13-24. [PMID: 12947221 DOI: 10.1385/IR:28:1:13] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 1.5] [Reference Citation Analysis]
137 Caldera H, Giralt S. Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia. Stem Cell Transplantation for Hematologic Malignancies 2004. [DOI: 10.1007/978-1-59259-733-8_2] [Reference Citation Analysis]
138 Scheffold C, Berdel WE, Kienast J. Hochdosistherapie und Stammzelltransplantation. Die Onkologie 2004. [DOI: 10.1007/978-3-662-06670-6_21] [Reference Citation Analysis]
139 Canals C, Martino R, Sureda A, Altés A, Briones J, Subirá M, Ancı́n I, Martı́n-henao G, Brunet S, Sierra J. Strategies to reduce transplant-related mortality after allogeneic stem cell transplantation in elderly patients: Comparison of reduced-intensity conditioning and unmanipulated peripheral blood stem cells vs a myeloablative regimen and CD34+ cell selection. Experimental Hematology 2003;31:1039-1043. [DOI: 10.1016/s0301-472x(03)00223-6] [Cited by in Crossref: 21] [Article Influence: 1.1] [Reference Citation Analysis]
140 Uoshima N, Kamitsuji Y, Maruya E, Saji H. Successful reduced-intensity stem cell transplantation from an HLA haploidentical 3-loci-mismatched donor on the basis of fetomaternal microchimerism in a patient with advanced acute myeloid leukemia. Int J Hematol 2003;78:69-72. [PMID: 12894854 DOI: 10.1007/BF02983243] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
141 Cesaro S, Gazzola MV, Marson P, Calore E, Caenazzo L, Destro R, De Silvestro G, Varotto S, Pillon M, Zanesco L, Messina C. Successful engraftment and stable full donor chimerism after myeloablation with thiotepa, fludarabine, and melphalan and CD34-selected peripheral allogeneic stem cell transplantation in hemophagocytic lymphohistiocytosis. Am J Hematol 2003;72:143-6. [PMID: 12555220 DOI: 10.1002/ajh.10266] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
142 Beguin Y, Baron F. Minitransplants: allogeneic stem cell transplantation with reduced toxicity. Acta Clin Belg 2003;58:37-45. [PMID: 12723260 DOI: 10.1179/acb.2003.58.1.005] [Reference Citation Analysis]
143 Bornhäuser M, Schaekel U, Schaich M, Soucek S, Ehninger G. Current Role of Allogeneic and Autologous Hematopoietic Stem Cell Transplantation in Patients with AML. Haematology and Blood Transfusion Hämatologie und Bluttransfusion 2003. [DOI: 10.1007/978-3-642-59358-1_79] [Reference Citation Analysis]
144 Robinson SP, Goldstone AH, Mackinnon S, Carella A, Russell N, de Elvira CR, Taghipour G, Schmitz N. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 2002;100:4310-4316. [DOI: 10.1182/blood-2001-11-0107] [Cited by in Crossref: 308] [Cited by in F6Publishing: 322] [Article Influence: 14.7] [Reference Citation Analysis]
145 Giralt S. Update on non-myeloablative stem cell transplantation for hematologic malignancies. Int J Hematol 2002;76 Suppl 1:176-83. [PMID: 12430850 DOI: 10.1007/BF03165241] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
146 Van Hoef ME. Nonmyeloablative transplantation challenged by experimentation. Blood 2002;100:1508; author reply 1508-9. [PMID: 12184273 DOI: 10.1182/blood-2002-02-0579] [Reference Citation Analysis]
147 Martino R, Caballero MD, de la Serna J, Díez-Martín JL, Urbano-Ispízua A, Tomás JF, Odriozola J, León A, Canals C, San Miguel J, Sierra J. Low transplant-related mortality after second allogeneic peripheral blood stem cell transplant with reduced-intensity conditioning in adult patients who have failed a prior autologous transplant. Bone Marrow Transplant 2002;30:63-8. [PMID: 12132043 DOI: 10.1038/sj.bmt.1703606] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 0.8] [Reference Citation Analysis]
148 Ruffner KL. Targeted radiotherapy as an adjunct to hematopoietic stem cell transplantation for advanced leukemia. Cancer Biother Radiopharm 2002;17:129-35. [PMID: 12030107 DOI: 10.1089/108497802753773757] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
149 Kim H. Mini-allogeneic stem cell transplantation. Cancer Pract 2002;10:170-2. [PMID: 11972573 DOI: 10.1046/j.1523-5394.2002.103003.x] [Reference Citation Analysis]
150 Shimoni A, Nagler A. Non-Myeloablative Hematopoietic Stem Cell Transplantation (NST) in the Treatment of Human Malignancies: From Animal Models to Clinical Practice. Non-Myeloablative Allogeneic Transplantation 2002. [DOI: 10.1007/978-1-4615-0919-6_6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
151 Martino R, Caballero MD, Canals C, Simón JA, Solano C, Urbano-Ispízua A, Bargay J, Rayón C, Léon A, Sarrá J, Odriozola J, Conde JG, Sierra J, San Miguel J; ALLOPBSCT Subcommittee of the Spanish Group for Haematopoietic Transplantation (GETH)., Group GEL-TAMO. Allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results of a prospective multicentre study. Br J Haematol 2001;115:653-9. [PMID: 11736950 DOI: 10.1046/j.1365-2141.2001.03153.x] [Cited by in Crossref: 88] [Cited by in F6Publishing: 92] [Article Influence: 4.0] [Reference Citation Analysis]
152 . Recent publications in hematological oncology. Hematol Oncol 2001;19:121-8. [PMID: 11574933 [PMID: 11574933 DOI: 10.1002/hon.673] [Reference Citation Analysis]
153 Bertz H. Allogeneic hematopoietic stem cell transplantation: . Current Opinion in Organ Transplantation 2001;6:259. [DOI: 10.1097/00075200-200109000-00010] [Reference Citation Analysis]
154 Conde E. [Allogeneic stem cell transplantation with reduced-intensity conditioning regimens. Another step towards curing by immunologic methods]. Med Clin (Barc) 2001;116:577-9. [PMID: 11412634 DOI: 10.1016/s0025-7753(01)71910-0] [Reference Citation Analysis]
155 Burroughs L, Woolfrey A. Hematopoietic cell transplantation for treatment of primary immune deficiencies. Cell Ther Transplant 2010;2. [PMID: 21152385 DOI: 10.3205/ctt-2010-en-000077.01] [Cited by in F6Publishing: 7] [Reference Citation Analysis]